Searching for semaglutide clinics near me can produce local medical practices, telehealth companies, med spas, and advertising pages. Proximity does not tell you who will prescribe, what product may be dispensed, which pharmacy will fill it, or what happens after payment.

Start with documentation. Before choosing a clinic, get seven answers in writing: the prescriber’s identity, the exact product, its regulatory status, the dispensing pharmacy, the safety and follow-up process, the complete price, and access to your records.

Seven checks at a glance

1. Verify the prescribing clinician

Ask who will make the prescribing decision. Get the clinician’s full name, professional designation, and state license number before paying a nonrefundable fee. Confirm the license through the official board for the state where you will receive care.

Do not assume the physician shown on an “About” page will be responsible for you. Ask who reviews your history, orders or interprets any required tests, issues the prescription, and handles follow-up. For telehealth care, confirm that clinician is permitted to treat patients in your state.

Our peptide-doctor verification guide explains how to compare a marketing claim with an official credential record.

2. Ask for the exact product identity

“Semaglutide program” is not a complete description. Ask whether the clinic proposes an FDA-approved brand product or a compounded preparation. Request the name that will appear on the prescription and dispensing label, the dosage form, and the legal name of the manufacturer or compounder.

FDA approval applies to a specific product, manufacturing process, labeling, and set of uses. It does not automatically extend to every item marketed with the same ingredient name. FDA states that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality.

Be cautious with phrases such as “generic semaglutide,” “same as the brand,” or “FDA-approved pharmacy.” FDA says compounded drugs are not generic drugs. The agency has also stated that pharmacies and outsourcing facilities are not designated “FDA-approved” or “FDA-licensed” businesses.

3. Separate approved products from compounded preparations

The current FDA prescribing information for Wegovy lists approved uses and important warnings for that specific semaglutide product. A clinic should identify the proposed product first and then explain whether the intended use matches its approved labeling. It should not blur an approved brand product with a compounded preparation.

Compounding can address a patient-specific need in appropriate circumstances, but it is not FDA approval. FDA says compounded drugs should be used when a patient’s needs cannot be met by an approved drug. FDA also determined that the national shortage of semaglutide injection products was resolved in 2025 and has since clarified the restrictions involving copies of commercially available products.

If a compounded product is proposed, ask the prescriber to explain the documented patient-specific reason. Ask whether the ingredient is semaglutide base or a salt form. FDA says semaglutide sodium and semaglutide acetate are different active ingredients from those used in approved products and that it is not aware of a lawful basis for their use in compounding.

Read our 503A and 503B pharmacy checklist for the differences these categories establish and the claims they do not prove.

4. Verify the pharmacy independently

Get the pharmacy’s full legal name and physical location before the first shipment. Look up its license through the appropriate state board. If the seller says the facility is registered as an outsourcing facility, compare that claim with FDA’s current list. Registration is verifiable, but it does not mean a particular compounded product is approved or appropriate for you.

Ask what information will appear on the dispensing label and how temperature-sensitive shipments are handled. The clinic should explain what to do if a delivery arrives warm, damaged, late, or with inconsistent labeling.

FDA reports complaints about improperly shipped compounded GLP-1 products and fraudulent labels naming pharmacies that did not make the product. Independent pharmacy verification is therefore more than paperwork.

5. Compare screening and follow-up

A clinic should explain its care process before requesting long-term payment. Ask what medical history is reviewed, whether records or laboratory results are required, which risks are screened, and who decides whether treatment is appropriate.

Ask how routine questions, side effects, missed visits, and urgent concerns are handled. Find out whether follow-up is included or billed separately and whether you can reach the prescribing clinician when the plan changes. An app or monthly shipment without a clear clinical contact is not a complete follow-up system.

The current Wegovy label contains a boxed warning plus multiple contraindications, warnings, precautions, and interaction considerations. This guide does not reproduce treatment instructions. It is a reason to insist that a licensed clinician review the current label and your health information with you.

6. Get the complete price and cancellation terms

Request one written price sheet covering the medical visit, medication, membership, laboratory work, shipping, supplies, follow-up, and cancellation. Confirm whether the advertised amount is introductory, whether the pharmacy bills separately, and whether unused subscription time is refundable.

Do not let price substitute for product identity. Clinics can advertise similar monthly programs while offering different products, pharmacy arrangements, clinician access, and cancellation rules. Compare the entire care package, not a headline price.

7. Confirm records and continuity

Ask how to obtain visit notes, prescription history, test results, and dispensing information. Confirm what happens if the clinician leaves, the pharmacy changes, the clinic closes, or you cancel. Other clinicians may need accurate information about what was prescribed and dispensed.

If a clinic will not identify the prescriber or pharmacy before payment, refuses records, or pressures you to pay before answering basic questions, step back. A promotion does not remove the need for an informed medical and financial decision.

What the STEP 1 trial shows

The 2021 STEP 1 trial was randomized, double-blind, and placebo-controlled. It involved adults with overweight or obesity who did not have diabetes. Participants received lifestyle intervention, and the semaglutide group experienced greater average weight reduction than the placebo group during the study. Gastrointestinal events were common, and more participants receiving semaglutide stopped treatment because of those events. The manufacturer funded the trial.

The study supports conclusions about a defined product, population, and research protocol. It does not prove that every clinic is qualified, that a compounded product is equivalent, or that an individual will experience the study’s average result. A clinic advertisement cannot borrow the trial’s credibility without identifying the product and care process it actually provides.

Red flags

• No clinician name or license available before payment.
• No pharmacy name or exact product identity on request.
• A compounded product described as FDA-approved, generic, or identical to a brand product.
• Guaranteed weight loss or testimonials presented as predictable outcomes.
• A questionnaire-only transaction with no clear follow-up contact.
• Unclear recurring charges, cancellation terms, or refund policy.
• Instructions to ignore the dispensing label or alter care without the prescriber.

Compare clinics by city

Use the Find Peptide Clinics city directory to compare local information, then verify every credential and product claim independently. Our GLP-1 clinic checklist and injection-clinic checklist provide additional consultation questions.

Find Peptide Clinics publishes source-checked directory information. Clinics may claim or correct a free listing and may separately request clearly labeled enhanced placement. Paid placement is not medical endorsement and does not replace credential or product verification.

Frequently asked questions

How do I verify a semaglutide clinic?

Confirm the prescriber through the state licensing board, identify the exact product and pharmacy, and obtain the care process and complete price in writing.

Is compounded semaglutide FDA-approved?

No. FDA states that compounded drugs are not FDA-approved. A compounded preparation may serve a patient-specific need under applicable law, but it does not undergo the same premarket review as an approved drug.

Does 503B registration mean a product is FDA-approved?

No. Registration identifies the facility’s regulatory category. It does not make its compounded products FDA-approved or establish that a product is appropriate for a patient.

What should I ask about the pharmacy?

Ask for its legal name, location, state license, facility category when relevant, label information, shipping process, and a direct contact for dispensing questions.

Should I choose the nearest clinic?

Convenience matters, but prescriber credentials, product identity, pharmacy transparency, follow-up, records, and total cost are stronger comparison factors.

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.
• FDA. Wegovy prescribing information, revised February 2026.
• FDA. Concerns with unapproved GLP-1 drugs used for weight loss, current through May 2026.
• FDA. Compounding and the FDA: Questions and Answers.
• FDA. Policies for compounders after the semaglutide shortage resolution, updated April 2026.

This article is educational and is not medical advice, diagnosis, or a treatment recommendation. Consult a licensed clinician who can review your health history and current prescribing information.